Multiple Sclerosis Treatment Global Market Report 2025

The multiple sclerosis treatment market size has grown strongly in recent years. It will grow from $24.86 billion in 2024 to $26.13 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. This growth during the historical period was driven by heightened awareness of early MS symptoms, expanded access to disease-modifying therapies, rising incidence of autoimmune disorders, improved neurological healthcare infrastructure, and growing use of immunomodulatory drugs.

The multiple sclerosis treatment market size is expected to see steady growth in the next few years. It will grow to $31.55 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. This anticipated growth is attributed to increasing approvals of novel monoclonal antibodies, heightened demand for personalized MS treatments, enhanced focus on managing neurodegenerative diseases, wider use of telemedicine in MS care, and a shift toward minimally invasive treatment approaches. Notable trends expected in the forecast period include advancements in remote monitoring technologies, the development of remyelination therapies, exploration of gut-brain axis approaches, the integration of digital biomarkers, and innovation in digital therapeutics.

The increasing prevalence of neurological disorders is anticipated to drive the growth of the multiple sclerosis treatment market. Neurological disorders are conditions that impact the brain, spinal cord, and nerves, resulting in challenges with movement, communication, behavior, or bodily functions. This rise in neurological conditions is primarily attributed to an aging population, as longer life expectancies heighten the risk of age-related disorders like Alzheimer’s disease. Multiple sclerosis treatments play a crucial role in managing such neurological issues by modulating the immune system to reduce inflammation, minimize nerve damage, and alleviate symptoms, ultimately enhancing patients’ quality of life. For example, in October 2023, the World Federation of Neurology, a UK-based organization representing national neurological societies, reported that over 40% of the global population is currently affected by some form of neurological condition, with this figure expected to nearly double by 2050. As a result, the rising prevalence of neurological disorders is significantly contributing to the expansion of the multiple sclerosis treatment market.

Companies operating in the multiple sclerosis treatment space are increasingly focusing on the development of advanced therapies, such as monoclonal antibody drugs, to improve treatment outcomes and efficacy. Monoclonal antibodies are lab-engineered molecules designed to target specific antigens, and in the context of multiple sclerosis, they work by minimizing inflammation and protecting nerve fibers from immune cell attacks, thereby slowing disease progression. For instance, in February 2024, Roche Pharma India, an Indian pharmaceutical company, launched Ocrevus (Ocrelizumab) to treat multiple sclerosis. This drug specifically targets CD20-positive B cells to reduce inflammation and nerve damage. It is the first therapy approved for both relapsing and primary progressive forms of MS and is known to significantly lower relapse rates and slow disability progression with the added benefit of biannual infusions.

In March 2024, Juvisé Pharmaceuticals, a pharmaceutical company based in France, acquired a multiple sclerosis drug from Actelion Pharmaceuticals Ltd. for an undisclosed amount. This acquisition aims to broaden Juvisé Pharmaceuticals' neurology portfolio beyond the US and Canadian markets, while also involving financial support from Bpifrance and Pemberton to back its future growth strategies. Actelion Pharmaceuticals Ltd., based in Switzerland, is a pharmaceutical company actively engaged in multiple sclerosis treatment development.

Major players in the multiple sclerosis treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Mallinckrodt Pharmaceuticals, Acorda Therapeutics Inc., Adamas Pharmaceuticals Inc., Mapi Pharma Ltd., TG Therapeutics Inc., Atara Biotherapeutics Inc.

North America was the largest region in the multiple sclerosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in multiple sclerosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the multiple sclerosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Multiple sclerosis (MS) treatment encompasses medical strategies and therapies designed to manage symptoms, slow disease progression, and enhance the quality of life for individuals with MS, a chronic autoimmune condition that impacts the central nervous system. These treatments include disease-modifying therapies (DMTs) and symptomatic interventions that address issues such as fatigue, muscle spasms, and mobility difficulties. The primary goal of MS treatment is to support neurological function and improve patients' overall well-being.

Key types of MS treatments include immunomodulators, corticosteroids, symptomatic therapies, monoclonal antibodies, and oral medications. Immunomodulators, such as interferon beta and glatiramer acetate, work by modifying immune system activity to reduce inflammation and prevent relapses. MS-related conditions include clinically isolated syndrome, relapsing-remitting MS, primary progressive MS, and secondary progressive MS. Treatment delivery methods include oral, injectable, and intravenous routes, and these are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The treatments cater to various end users, including hospitals, specialty clinics, homecare settings, and others.

The multiple sclerosis treatment market research report is one of a series of new reports that provides multiple sclerosis treatment market statistics, including the multiple sclerosis treatment industry's global market size, regional shares, competitors with the multiple sclerosis treatment market share, detailed multiple sclerosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis treatment industry. This multiple sclerosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multiple sclerosis treatment market consists of sales of products including disease-modifying therapies, synthetic polypeptides, cannabinoid-based therapies, interferon beta products, and plasma exchange. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.